Us Congress 2023-2024 Regular Session

Us Congress Senate Bill SB2924

Introduced
9/26/23  
Refer
9/26/23  

Caption

STEP Act Safeguarding the Transparency and Efficiency of Payments Act

Impact

If enacted, the bill will amend existing law by requiring federal agencies to submit comprehensive reports to Congress regarding their implementation of fraud risk management strategies. By holding agencies accountable for their actions related to financial control and fraud prevention, SB2924 is expected to improve transparency in government spending and enhance the efficiency of payment systems. This legislative measure aims to not only encourage best practices but also highlight areas within agencies that are susceptible to significant improper payments, particularly in programs with substantial financial outlays.

Summary

SB2924, known as the 'Safeguarding the Transparency and Efficiency of Payments Act' or the 'STEP Act', seeks to amend Title 31 of the United States Code to enhance the management of improper payments across federal agencies. The bill emphasizes the importance of establishing robust financial and administrative controls aimed at identifying and curbing fraud risks tied to agency operations. Specifically, the legislation mandates annual reporting requirements, urging agencies to clarify the status of their fraud management practices and provide detailed updates regarding the measures taken to prevent improper payments.

Sentiment

The general sentiment surrounding SB2924 appears to be favorable, particularly among those advocating for greater government accountability and fiscal responsibility. Supporters view the bill as a necessary step to ensure the effective use of taxpayer funds and to combat the prevalence of fraud within federal programs. However, there may be some skepticism regarding the actual enforcement of the provisions and whether agencies will fully comply with the reporting requirements outlined in the legislation.

Contention

Notable points of contention may arise regarding how the bill defines 'improper payments' and the thresholds set for identifying programs susceptible to such payments. Critics might also raise concerns about the potential for overregulation or bureaucratic red tape that could arise from the mandated reporting requirements. The success of the bill in achieving its objectives will largely depend on the political will of Congress to enforce accountability among federal agencies and ensure that they take the necessary corrective measures to manage fraud effectively.

Companion Bills

No companion bills found.

Similar Bills

US SB5310

Federal Acquisition Security Council Improvement Act of 2024

US SB4700

Improving Federal Financial Management Act

US SB3593

Truckee Meadows Public Lands Management Act

US SB1764

Western Wildfire Support Act of 2024

US SB3392

AREA Act Advancing Research in Education Act Educational Technical Assistance Act of 2002

US SB3312

Artificial Intelligence Research, Innovation, and Accountability Act of 2024

US SB331

Halt All Lethal Trafficking of Fentanyl Act or the HALT Fentanyl ActThis bill permanently places fentanyl-related substances as a class into schedule I of the Controlled Substances Act. A schedule I controlled substance is a drug, substance, or chemical that has a high potential for abuse; has no currently accepted medical value; and is subject to regulatory controls and administrative, civil, and criminal penalties under the Controlled Substances Act.Under the bill, offenses involving fentanyl-related substances are triggered by the same quantity thresholds and subject to the same penalties as offenses involving fentanyl analogues (e.g., offenses involving 100 grams or more trigger a 10-year mandatory minimum prison term).Additionally, the bill establishes a new, alternative registration process for certain schedule I research.The bill also makes several other changes to registration requirements for conducting research with controlled substances, includingpermitting a single registration for related research sites in certain circumstances,waiving the requirement for a new inspection in certain situations, andallowing a registered researcher to perform certain manufacturing activities with small quantities of a substance without obtaining a manufacturing registration.Finally, the bill expresses the sense that Congress agrees with the interpretation of the Controlled Substances Act in United States v. McCray, a 2018 case decided by the U.S. District Court for the Western District of New York. In that case, the court held that butyryl fentanyl, a controlled substance, can be considered an analogue of fentanyl even though, under the Controlled Substances Act, the term controlled substance analogue specifically excludes a controlled substance.

US SB3606

National Earthquake Hazards Reduction Program Reauthorization Act of 2024